Core Viewpoint - Shanghai Jianda Zhixin Medical Technology Group Co., Ltd. has applied for the IPO review status change to "submitted for registration" on the Shenzhen Stock Exchange's ChiNext, aiming to raise 484.24 million yuan [1] Company Overview - Jianda Zhixin is a national high-value medical device distributor, primarily engaged in direct sales and distribution of medical devices, providing centralized operation services for medical consumables to terminal hospitals [1][2] - The company has established a distribution network covering over 3,300 terminal medical institutions across 31 provinces, municipalities, and autonomous regions in China, offering thousands of specifications and models of direct sales services [2] Financial Performance - The company's projected operating revenues for 2022, 2023, and 2024 are 11.882 billion yuan, 15.443 billion yuan, and 17.923 billion yuan, respectively, with year-on-year growth rates of 29.97% and 16.06% for 2023 and 2024 [2] - Net profits for the same periods are expected to be 189 million yuan, 227 million yuan, and 274 million yuan, reflecting year-on-year increases of 19.90% and 20.68% for 2023 and 2024 [2] Fundraising and Investment Plans - The funds raised will be allocated to the following projects: - Information system upgrade project: 140.16 million yuan - Centralized operation service project for medical consumables: 104.08 million yuan - Supplementing working capital: 240 million yuan - Total investment: 484.24 million yuan [2] Key Financial Metrics - As of December 31, 2024, the company expects to achieve a net profit attributable to shareholders of 228.31 million yuan, with a basic earnings per share of 0.64 yuan [4] - The company's total assets are projected to reach 1.311 billion yuan, with a debt-to-asset ratio of 79.32% for the parent company [5]